Mode
Text Size
Log in / Sign up

Hepatocellular carcinoma (HCC)

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatocellular carcinoma (HCC)

9 trials tracked for Hepatocellular carcinoma (HCC): 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 275 citations.

9Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 5 Phase 1 1
  1. Phase 3 A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) Completed · 275 cited
  2. Phase 3 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Completed · 149 cited
  3. Phase 3 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Completed
  4. Phase 2 Study of BGB-A317 in Participants With Previously Treated Unresectable HCC Completed
  5. Phase 2 IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Completed
  6. Phase 2 FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression Completed
Show 3 more trials
  1. Phase 2 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed
  2. Phase 2 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer Completed
  3. Phase 1 A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hepatocellular carcinoma (HCC): what the trials found

Tislelizumab has demonstrated statistically significant improvements in both Overall Survival (OS) and Objective Response Rate (ORR) for patients with hepatocellular carcinoma. In a Phase 3 trial, Tislelizumab showed an OS of 15.9 months compared to 14.1 months (p=0.0398) and a BIRC-assessed ORR of 14.3% compared to 5.4% (p=0.0003) 1. A separate Phase 2 trial also confirmed a significant ORR of 12.9% (p=0.0001) with Tislelizumab 6.

Other established treatments for hepatocellular carcinoma include Lenvatinib 2 and Pexastimogene Devacirepvec (Pexa Vec) 3.

Recent results — preliminary, needs further review

  • Pembrolizumab was evaluated in a Phase 2 trial 4.

For the clinician treating this condition

  • Tislelizumab is associated with statistically significant improvements in OS and ORR in patients with hepatocellular carcinoma [1, 6].
  • Lenvatinib and Pexastimogene Devacirepvec (Pexa Vec) are established interventions for this condition [2, 3].

AI synthesis of 5 cited trials, updated Oct 1, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.